Farmacie pro praxi. 2023;19(2):8-13 [Neurol. praxi. 2022;23(6):483-487]

Eptinezumab - the new anti-CGRP monoclonal antibody for prophylactic treatment of migraine

Rudolf Kotas
Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika LF UK a FN Plzeň

Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine. Eptinezumab is the first intravenous monoclonal antibody targeting the molecule of CGRP which is used for the preventive treatment of migraine. In this paper the pharmacology of eptinezumab and five successful Phase III clinical studies are reviewed. The study PROMISE-1 evaluates the efficacy, safety and tolerability of eptinezumab in the preventive treatment of episodic migraine, the study PROMISE-2 is the same in chronic migraine. The study PREVAIL evaluates the long-term safety, immunogenicity and patient-reported efficacy with help of standard questionnaires in the period of two years. The study RELIEF evaluates the efficacy of eptinezumab when administered during migraine attack. Finally, the study DELIVER evaluates the efficacy and safety of eptinezumab in the preventive treatment of migraine in patients with two-to-four previous preventive treatment failures. The results of these studies show that eptinezumab is effective and well-tolerated for the preventive treatment of migraine. At the end some practical comments to the treatment with eptinezumab in clinical practice are mentioned.

Keywords: eptinezumab, calcitonin gene­‑related peptide (CGRP), migraine, anti­‑CGRP monoclonal antibody, clinical studies, preventive migraine treatment.

Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotas R. Eptinezumab - the new anti-CGRP monoclonal antibody for prophylactic treatment of migraine. Pharmacy for Practice. 2023;19(2):8-13.
Download citation

References

  1. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of brain in Europe. Eur J Neurol. 2005;12(Suppl1):1-27. doi 10.1111/j.1468-1331.2005.01202.x. Go to original source... Go to PubMed...
  2. Ashina M, Lanteri­‑Minet M, Pozo­‑Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomized, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607. Go to original source...
  3. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. doi: 10.1177/0333102420905132. Go to original source... Go to PubMed...
  4. Dodick DW, Lipton RB, Silberstein S. Eptinezumab for prevention of chronic migraine. A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085. doi: 10.1177/0333102419858355. Go to original source... Go to PubMed...
  5. Dodick DW, Silberstein SD, Lipton RB, et al. Safety and efficacy of ALD 403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomized, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100-1107. http://dx.doi.org/10.1016/S1474-4422(14)70209-1. Go to original source... Go to PubMed...
  6. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. doi 10.1038/s41582-018-0003. Go to original source...
  7. Edvinsson JCA, Warfvinge K, Krause DN, at al. C-fibers may modulate adjacent Adelta fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. The Journal of Headache and Pain. 2019;20(1):105. doi.10.1186/s10194-019-1055-3. Go to original source... Go to PubMed...
  8. GBD 2016 Headache Collaborators Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954-976. Go to original source...
  9. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48/56. Go to original source...
  10. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann Neurol. 1990;28:183-187. Go to original source...
  11. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211. Go to original source...
  12. Kamm K, Straube A, Ruschewegh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia. 2019, https://doi.org/10.1177/0333102419856640. Go to original source... Go to PubMed...
  13. Kotas R. Bolesti hlavy v klinické praxi. Praha: Maxdorf, 2015, 312 s. ISBN 978-80-7345-443-2.
  14. Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurology. 2021;21:126. https://doi.org/10.1186/s12883-021-02123-w. Go to original source... Go to PubMed...
  15. Lassen LH, Harderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22: 54-61. Go to original source... Go to PubMed...
  16. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1-e13. doi: 10.1212/WNL.0000000000009169. Go to original source... Go to PubMed...
  17. Martinez-Villar MD, Moreno-Ajova D, Goadsby PJ. Eptinezumab for the preventive treatment of migraine. Pain Manag. 2021;11(2):113-121. doi: 10.2217/pmt-2020-0075. Go to original source... Go to PubMed...
  18. Nežádal T. CGRP monoklonální protilátky v profylaktické léčbě migrény. Neurol. praxi. 2019;20(5):356-360. Go to original source...
  19. Nežádal T, Marková J, Bártková A, et al. CGRP monoklonální protilátky v léčbě migrény - indikační kritéria a terapeutická doporučení pro Českou republiku. Cesk Slov Neurol N. 2020;83/116(4):445-451. doi 10.14735/amcsnn2020445. Go to original source...
  20. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386-398. doi 10.1038/nrn1102. Go to original source... Go to PubMed...
  21. Souhrn údajů o přípravku eptinezumab (Vyepti)- H. Lundbeck AIS, Ottiliavej 9, 2500 Valby, Dánsko (v tisku).
  22. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in US workforce. JAMA. 2003;290(18):2443-2454. doi 10.1001/jama290.18.2443. Go to original source... Go to PubMed...
  23. Winner PK, Mc Allister P, Chakhava G, et al. Effects of Intravenous Eptinezumab on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack. A Randomized Clinical Trial. JAMA. 2021;325(23):2348-2356. doi: 10.1001/jama.2021.7665. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.